Equity Capital Markets: Experience

  • Prothena Corporation plc on numerous NASDAQ equity raises totaling over $750m including its (i) underwritten equity offerings in March 2021, March 2017, January 2016, April 2015 and June 2014 and (ii) its May 2021 ATM programme and its June 2026 ATM programme.

  • Iterum Therapeutics plc on several NASDAQ equity raises totalling over $100m including its underwritten equity offerings, registered direct offerings, the issue of Exchangeable Senior Notes, rights offerings, including the first fully pre-emptive rights offering by a US listed Irish plc.

  • Nabriva Therapeutics plc on multiple NASDAQ equity raises totaling over $300m including its (i) underwritten equity offerings in July 2018 and September 2017 (ii) registered direct offerings in March 2021, December 2020, May 2020 and December 2019 and (iii) its June 2019 and March 2018 ATM programmes.

  • Jazz Pharmaceuticals plc on numerous hybrid offerings, including the issuance of its $1bn Exchangeable Senior Notes due 2026, its $575m Exchangeable Senior Notes due 2024 and its $575m Exchangeable Senior Notes due 2021 by way of private placement.

  • Osmotica Pharmaceuticals plc on several NASDAQ equity raises worth up to $135m including its (i) underwritten equity offerings in July and January 2020 and (ii) its September 2021 ATM programme.

  • GH Research plc on its (i) February 2025 under equity offering of its ordinary shares for a total equity raise of $150m, (ii) April 2026 underwritten registered direct offering of its ordinary shares for a total equity raise of $117,500,000 and (iii) $200m “At-The-Market” offering in May 2026.

  • OneView Healthcare plc, the only Irish-incorporated company listed on the Australian Securities Exchange on Irish corporate governance matters and also advised on the Irish law aspects of its 2024 placement of CHESS Depositary Interests over fully paid ordinary shares, which raised approximately AUD$20m.

  • Corre Energy on its equity fundraising of €2.7m by way of subscription and private placing.

  • Avadel Pharmaceuticals plc on the issuance of its c.$145m Exchangeable Senior Notes due 2023 by way of private placement.

  • Goodbody Stockbrokers on the €25m equity financing of Datalex by way of firm placing and placing and open offer.

  • Permanent TSB Group Holdings plc on its Odd-lot Offer.

  • Numis Securities Limited on the admission to trading of ordinary shares of Aquila European Renewables plc on Euronext Growth Dublin.

  • J&E Davy as sole financial advisor to DCC plc in their £600m tender offer process.

  • UltraGreen/Renew Pharmaceuticals on its $400m IPO on the Singaporean Stock Exchange.

  • J.P. Morgan as underwriters as underwriters on the $1.05bn initial public offering and NYSE listing of NIQ Global Intelligence plc.

  • J&E Davy and RBC on the IPO of Uniphar.

  • Hibernia REIT plc on all of its equity capital markets and related transactions including (i) on its dual primary listing on the Irish and London Stock Exchanges (official lists) (ii) its related €385m equity fundraising (iii) its subsequent €300m placing and open offer.